Trastuzumab deruxtecan + Durvalumab + Paclitaxel + Pertuzumab + Tucatinib
Phase 1/2Active 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Trial Timeline
Dec 28, 2020 → Jan 31, 2030
NCT ID
NCT04538742About Trastuzumab deruxtecan + Durvalumab + Paclitaxel + Pertuzumab + Tucatinib
Trastuzumab deruxtecan + Durvalumab + Paclitaxel + Pertuzumab + Tucatinib is a phase 1/2 stage product being developed by Daiichi Sankyo for Metastatic Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04538742. Target conditions include Metastatic Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
9
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04538742 | Phase 1/2 | Active |
Competing Products
20 competing products in Metastatic Breast Cancer